A stronger version of the popular weight loss drug Wegovy is on the way after federal regulators signed off on a higher dose. The U.S. Food and Drug Administration (FDA) approved a 7.2-milligram dose of Novo Nordisk's semaglutide, ...
Mar 23, 2026
0
5
A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 randomized controlled trial ...
Feb 26, 2026
0
28
Playing video games for more than 10 hours a week could have a significant impact on young people's diet, sleep and body weight, according to a new Curtin University-led study published in Nutrition.
Jan 15, 2026
0
30
For years, endocrinologist Leigh Perreault, MD, felt there had to be a better way to help patients with weight management than sending them home with advice to change their diet and increase their exercise.
Jan 14, 2026
0
52
A Curtin University-led study has found that where Australians live has a measurable influence on their body weight, with local food environments and neighborhood design playing a big part in shaping health outcomes.
Dec 2, 2025
0
5
A Novo Nordisk-designed trial, conducted at 68 international hospitals, specialist clinics, and medical centers with investigators from University of Texas Southwestern Medical Center and other institutions, reports greater ...
In sports such as wrestling, boxing, rowing, weight lifting and the martial arts, athletes are grouped by weight to make things fairer.
Aug 30, 2025
0
23
When given nutritionally matched diets, participants lost twice as much weight eating minimally processed foods compared to ultra-processed foods, suggesting that cutting down on processing could help to sustain a healthy ...
Aug 4, 2025
0
47
For adults with overweight or obesity, time-restricted eating (TRE) does not lead to significant changes in sleep, mood, or quality of life, regardless of the timing of the eating window, according to a study published online ...
Jul 3, 2025
0
14
For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist known as ecnoglutide yields a superior and sustained reduction in body weight ...
Jun 23, 2025
0
22
